Free tool
FAERS Monitor: Enhertu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761139 or its brand name (Enhertu, Fam-Trastuzumab Deruxtecan-Nxki). Reports on generic versions are filed under their own applications.
Reports
10,910
Serious
8,277
76% of reports
Hospitalization
2,628
Death reported
2,791
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death1,336
- nausea1,288
- disease progression1,257
- interstitial lung disease1,100
- fatigue858
- off label use846
- diarrhoea632
- vomiting593
- pneumonitis441
- decreased appetite410
- asthenia407
- no adverse event381
- alopecia366
- dyspnoea348
- metastases to central nervous system279
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2019 | 4 |
| 2020 | 380 |
| 2021 | 717 |
| 2022 | 1,274 |
| 2023 | 1,808 |
| 2024 | 2,028 |
| 2025 | 2,248 |
| 2026 | 2,450 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,249 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| interstitial lung diseaseSignal | 1,100 | 44.8 | 42.3 | 46,089 |
| metastases to central nervous systemSignal | 279 | 42.6 | 37.9 | 11,055 |
| pneumonitisSignal | 441 | 31.7 | 28.9 | 12,894 |
| disease progressionSignal | 1,257 | 20.7 | 19.6 | 23,415 |
| no adverse eventSignal | 381 | 4.1 | 3.7 | 882 |
| alopeciaSignal | 366 | 3.6 | 3.3 | 689 |
| decreased appetiteSignal | 410 | 3.4 | 3.1 | 701 |
| nauseaSignal | 1,288 | 3.1 | 3.0 | 1,948 |
| deathSignal | 1,336 | 3.0 | 2.8 | 1,843 |
| vomitingSignal | 593 | 2.4 | 2.3 | 510 |
| fatigueSignal | 858 | 2.1 | 2.0 | 529 |
| astheniaSignal | 407 | 2.1 | 1.9 | 234 |
| diarrhoea | 632 | 1.9 | 1.8 | 271 |
| off label use | 846 | 1.9 | 1.7 | 352 |
| dyspnoea | 348 | 1.2 | 1.1 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.